Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 14/20 | 0.70 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239372 | 0.84 | PTGER1 (0.76) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL4152215 | 0.82 | PTGER1 (1.00) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL2961497 | 0.81 | PTGER1 (0.71) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13239359 | 0.81 | PTGER1 (0.91) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL2958646 | 0.81 | PTGER1 (1.00) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13239376 | 0.81 | PTGER1 (0.80) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13239367 | 0.80 | PTGER1 (0.85) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL2956473 | 0.79 | PTGER1 (0.62) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13239373 | 0.79 | PTGER1 (0.84) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R | |
| SCHEMBL13239369 | 0.79 | PTGER1 (0.85) | PTGER1MRGPRX4CYP1A2CYP2C9TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759369-B2 | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759369-B2 | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759369-B2 | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-2053042-A1 | Pyridine compounds for the treatment of prostaglandin mediated diseases | Glaxo Group Limited (GB) | 2009-04-29 | — | — | EP | disclosed |
| EP-1833795-B1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1833795-B1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | MARTIN PAUL GIBLIN GERARD | 2008-10-09 | — | — | US | disclosed |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | MARTIN PAUL GIBLIN GERARD | 2008-10-09 | — | — | US | disclosed |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | MARTIN PAUL GIBLIN GERARD | 2008-10-09 | — | — | US | disclosed |
| EP-1833795-A1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006066968-A1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | PTGER1, PTGDR, PTGER2 | PTGER1 1/4885MRGPRX4 25/4885CYP1A2 241/4885 |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | PTGER1, PTGDR, PTGER4 | PTGER1 1/4885MRGPRX4 32/4885CYP1A2 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.